Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer

Cancer Science

Volumn 109, Issue 3, 2018, Pages 814-820

  Amatatsu, Masahiko ^a   Arigami, Takaaki ^a   Uenosono, Yoshikazu ^a   Yanagita, Shigehiro ^a   Uchikado, Yasuto ^a   Kijima, Yuko ^a   Kurahara, Hiroshi ^a   Kita, Yoshiaki ^a   Mori, Shinichiro ^a   Sasaki, Ken ^a   Omoto, Itaru ^a   Maemura, Kosei ^a   Ishigami, Sumiya ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

gastric cancer; liquid biopsy; peripheral blood; prognosis; programmed death ligand 1

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; CD274 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA COLLECTION METHOD; DISTANT METASTASIS; FEMALE; GASTRECTOMY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; STOMACH CANCER; TUMOR INVASION; TUMOR VOLUME; BLOOD; GENE EXPRESSION REGULATION; GENETICS; LIQUID BIOPSY; MIDDLE AGED; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIQUID BIOPSY; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; UP-REGULATION;

EID: 85042130949     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13508     Document Type: Article

References (22)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654-2664.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61.
4. Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev. 2017;54:74-86.
5. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
6. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887-3895.
7. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-1369.
8. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007;13:5271-5279.
9. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.
10. Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102-4109.
11. Eto S, Yoshikawa K, Nishi M, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 2016;19:466-471.
12. Takada K, Toyokawa G, Okamoto T, et al. A comprehensive analysis of programmed cell death ligand-1 expression with the clone SP142 antibody in non-small-cell lung cancer patients. Clin Lung Cancer. 2017;18:572-582.
13. Arigami T, Uenosono Y, Yanagita S, et al. Clinical significance of circulating tumor cells in blood from patients with gastric cancer. Ann Gastroenterol Surg. 2017;1:60-68.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th edn. New York, NY: Springer; 2010.
15. Arigami T, Natsugoe S, Uenosono Y, et al. Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg. 2006;243:341-347.
16. David R. PD-L1 expression by circulating breast cancer cells. Lancet Oncol. 2015;16:e321.
17. Böger C, Behrens HM, Mathiak M, Krüger S, Kalthoff H, Röcken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016;7:24269-24283.
18. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
19. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717-726.
20. Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016;107:107-115.
21. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
22. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46-54.